Daniel Deangelo
Hematology & Oncology · Boston, MANPI 1134104920
Payments from drug & device makers
Across 536 payments — averaging $53,229 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$18.5M
- Novartis$6M
- Blueprint Medicines Corporation$1.5M
- Servier Bioinnovation$958K
- AbbVie$868K
- Adaptive Biotechnologies Corporation$147K
- plus $610K from 26 others
Across 24 payments — averaging $1173.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$21K
- Novartis$4K
- Bristol Myers Squibb$3K
- Novartis Pharma AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 64 | $18,454,352 |
| Novartis | 38 | $5,960,475 |
| Blueprint Medicines Corporation | 151 | $1,533,475 |
| Servier Bioinnovation | 103 | $958,264 |
| AbbVie | 16 | $867,835 |
| Adaptive Biotechnologies Corporation | 7 | $146,696 |
| Sanofi US Services Inc. | 6 | $125,161 |
| Bristol Myers Squibb | 21 | $99,296 |
| Institut DE Recherches Servier | 2 | $97,216 |
| Immunogen, Inc. | 6 | $85,867 |
| Gilead(2 entities) | 21 | $64,126 |
| E.r. Squibb & Sons, L.L.C. | 12 | $23,463 |
| Amgen | 13 | $19,332 |
| Jazz Pharmaceuticals Inc. | 8 | $14,111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $12,498 |
| Servier Pharmaceuticals LLC | 12 | $11,888 |
| Autolus Inc | 2 | $8,650 |
| Daiichi Sankyo Inc. | 6 | $6,894 |
| GSK | 6 | $5,979 |
| AstraZeneca | 3 | $5,814 |
| Eli Lilly | 1 | $4,934 |
| Astellas Pharma US Inc | 1 | $4,563 |
| Incyte Corporation | 7 | $3,685 |
| Geron Corporation | 5 | $3,491 |
| Sobi, Inc | 1 | $2,775 |
| Syndax Pharmaceuticals, Inc. | 2 | $2,408 |
| Merck | 1 | $2,240 |
| Agios Pharmaceuticals, Inc. | 2 | $2,221 |
| Intuitive Surgical | 6 | $1,152 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,028 |
| CTI Biopharma Corp. | 1 | $900 |
| Pfizer Corporation Hong Kong Limited | 1 | $27 |
How this compares
$28,530,815 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
- Panagiotis KonstantinopoulosBoston$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.